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Abstract
Importance of the field—Metal oxide nanoparticles, including zinc oxide, are versatile
platforms for biomedical applications and therapeutic intervention. There is an urgent need to
develop new classes of anticancer agents, and recent studies demonstrate that ZnO nanomaterials
hold considerable promise.
Areas covered in this review—This review analyzes the biomedical applications of metal
oxide and ZnO nanomaterials under development at the experimental, preclinical, and clinical
levels. A discussion regarding the advantages, approaches, and limitations surrounding the use of
metal oxide nanoparticles for cancer applications and drug delivery is presented. The scope of this
article is focused on ZnO, and other metal oxide nanomaterial systems, and their proposed
mechanisms of cytotoxic action, as well as current approaches to improve their targeting and
cytotoxicity against cancer cells.
Take home message—Through a better understanding of the mechanisms of action and
cellular consequences resulting from nanoparticles interactions with cells, the inherent toxicity and
selectivity of ZnO nanoparticles against cancer may be further improved to make them attractive
new anti-cancer agents.
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1. Introduction
Nanotechnology represents a new and enabling platform that promises to provide a broad
range of novel uses and improved technologies for biological and biomedical applications.
One of the reasons behind the intense interest is that nanotechnology permits the controlled
synthesis of materials where at least one dimension of the structure is less than 100 nm. This
ultra-small size is comparable to naturally occurring proteins and biomolecules in the cell
[1], and is notably smaller than the typical diameter (~7 μm) of many human cells. The
reduction of materials to the nanoscale can frequently alter their electrical, magnetic,
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structural, morphological, and chemical properties enabling them to interact in unique ways
with cell biomolecules and enable their physical transport into the interior structures of cells.
Nanoscale particles typically possess a larger percentage of atoms at the material’s surface,
which can lead to increased surface reactivity [2], and can maximize their ability to be
loaded with therapeutic agents to deliver them to target cells. By appropriate engineering
design these nanomaterials can acquire the ability to selectively target particular types of
cells or to pass through physiological barriers and penetrate deep into tumor sites.
The application of nanotechnology to medical applications, commonly referred to as
“nanomedicine”, seeks to deliver a new set of tools, devices and therapies for treatment of
human disease. Nanomaterials that can act as biological mimetics, “nanomachines”,
biomaterials for tissue engineering, shape-memory polymers as molecular switches,
biosensors, laboratory diagnostics, and nanoscale devices for drug release, are just a few of
the applications currently being explored [3–5]. Already, nanomedicine represents an
emerging industry with the US National Science Foundation predicting that the market for
nanotechnology containing products will reach one trillion US dollars in 10–15 years [6]. As
such, there is considerable interest in the role of nanomaterials for the rational delivery and
targeting of pharmaceutical and diagnostics agents for the treatment of cancer. The potential
use of ZnO and other metal oxide nanoparticles in biomedical and cancer applications is
gaining interest in the scientific and medical communities, largely due to the physical and
chemical properties of these nanomaterials, and is the focus of this article.
1.1. Cancer Treatment Today
Cancer is reported as the second leading cause of death in the US and accounts for ~25% of
all deaths [4]. Even more serious is the recent projection by the World Health Organization,
which anticipates total cancer cases will more than double by the year 2030 from the 12.4
million new cases seen in 2008 [7]. Despite the fact that scientific understanding of the
functioning of the human body at the molecular level has improved tremendously, advances
in therapeutic options for cancer have lagged by comparison. Current anticancer
chemotherapies based on alkylating agents, antimetabolites, biological agents, and natural
products frequently fail to produce a complete anti-cancer response due to the development
of drug resistance or their failure to effectively differentiate between cancerous and normal
cells. This indiscriminate action frequently leads to systemic toxicity and debilitating
adverse effects in normal body tissues including bone marrow function suppression,
neurotoxicity, and cardiomyopathy, which greatly limits the maximal allowable dose of the
chemotherapeutic drug [8,9]. In this regard, recent studies have shown that ZnO
nanoparticles exhibit a high degree of cancer cell selectivity with the ability surpass the
therapeutic indices of some commonly used chemotherapeutic agents in similar ex vivo
studies [10,11]. In addition, the rapid elimination or widespread dissemination of the anti-
cancer drug across non-target tissues requires drug administration in large quantities which
can further complicate problems related to non-specific toxicity. Thus, there is an urgent
need to develop new classes of anticancer drugs with new modes of action that better target
cancer cells while sparing healthy tissues.
1.2. Overview of Nanotechnology in Cancer Applications
Nanobiotechnology has been viewed as having the potential to offer a more targeted
approach capable of providing significant treatment improvements for cancer patients. The
underlying rationale is that reduction of materials of the nanoscale can sometimes lead to the
development of new structural, physiochemical, electronic, and magnetic properties that are
not present in larger bulk-sized (micron or larger) particles comprised of the same material
systems. It is these new properties that can potentially lead to unique biological and medical
applications. A growing number of research groups have shown that low concentrations of
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nanomaterials, including metal oxide nanoparticles, can kill human cancer cells while their
larger micron-sized counterparts are comparatively non-toxic [2,10,12–16]. Even more
compelling are recent in vitro observations indicating that certain types of metal oxide
nanoparticles can preferentially kill cancer cells with strikingly less toxicity against normal
cells [10,11]. As a natural outcropping of these studies, there is considerable interest in
further improving nanoparticle specificity and anti-cancer properties by functionalizing them
with antibodies or other ligands directed against cancer-associated molecules [17].
Nanomaterials are also being explored for use in intracellular delivery of DNA, RNAi,
proteins, peptides and small drugs for inducing cancer cell death, as contrast agents for
cancer imaging, and as platforms for targeted gene and chemotherapeutics delivery to tumor
sites [4,17].
2. Significance of Nanomaterial Physical Properties and Biological
Applications
The integration of nanotechnology and biology provides the opportunity for the
development of new materials in the nanometer size range that can be applied to many
potential applications in clinical medicine [1,18]. The most widely studied type of
nanomaterials is the nanoparticle, which is largely due to their ease and efficiency of
production from a variety of materials. When reduced to the nanoscale, unique size-
dependent properties of nanoparticles are manifested [2]. The principal factors believed to
cause properties of nanomaterials to differ from their larger micron-sized bulk counterparts
include an increase in relative surface area, a greater percentage of atoms at the material’s
surface, quantum effects which can affect chemical reactivity, and other physical and
chemical properties [2,18]. The positioning of the vast majority of nanostructure atoms at
the material’s surface maximizes their ability to be loaded with therapeutic drugs, and to
deliver these agents to target cells and tissues.
The size of nanoparticles, which is comparable to naturally occurring biological molecules,
is another feature that makes them well suited for biological applications. Their nanoscale
size allows their internalization into cells, and allows them to interact with biomolecules
within or on the cell surface, enabling them to potentially affect cellular responses in a
dynamic and selective manner. The size of nanoparticles can facilitate their entry into tumor
tissues, and their subsequent retention, by a process recognized as the enhanced permeation
and retention (EPR) effect. Therapeutic approaches making use of the EPR effect are now
recognized as the “gold-standard” in the design of new anti-cancer agents. The EPR
phenomena can be described as a combination of “leaky” tumor blood vessels due to
alterations in angiogenic regulators, enlarged gap junctions between endothelial cells, and
compromised lymphatic drainage in the tumor microenvironment. This localized imbalance
allows nanoparticles of certain sizes [19] to readily enter, but to be passively retained within
the tumor interstitial space, thereby improving therapeutic potential. In a recent report,
particles of 100–200 nm size showed a 4-fold higher rate of tumor uptake compared to
particles greater than 300 nm, or less than 50 nm in size [20]. Although smaller
nanoparticles don’t readily make use of the EPR/enhanced permeation and retention effect,
they typically exhibit more nanotoxicity related to their larger surface area/volume ratio
[19,20]. These seemingly conflicting actions with respect to nanoparticle size and anti-tumor
activity can make it difficult to reliably predict nanoparticle characteristics likely to provide
the best therapeutic efficacy without direct testing.
The electrostatic nature of nanoparticles is another important consideration as electrostatic
interactions between positively charged nanomaterials and target cells are believed to play
an important part in cellular adhesion and uptake [21]. Compared to normal eukaryotic cells
whose outer leaflet consists of neutral charged zwitterionic phospholipids [22], cancer cells
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frequently maintain a high concentration of anionic phospholipids on their outer leaflet and
large membrane potentials [23–25], and over-express specific groups of charged proteins
and carbohydrates [5]. In addition, studies have shown that intracellular pH increases with
cell cycle progression and proliferation [26,27], which could affect electrostatically-driven
interactions with charged particles at the cell membrane. Even more compelling is data
demonstrating that while polycationic polymer particles and cationic fullerenes cause
substantial disruption of biomembranes, their neutral or negatively charged counterparts fail
to cause measurable effect [28]. While nanoparticles with higher positive charge may be
desirable for higher toxicity to cancer cells, very high positive charge may not be suitable
for in vivo cancer treatment due to rapid serum clearance [29]. Thus, tailoring the surface
charge of nanoparticles is expected to influence their cytotoxicity and will likely be an
important parameter for developing cancer therapies.
The overall shape and morphology of the nanomaterial is another important consideration
for biomedical applications. In addition to nanoparticles, which are roughly spherical in
structure, there are two-dimensional thin films which have been utilized for more than 40
years. There is also a class of one-dimensional nanostructures, commonly referred to as
nanowires, which have cylindrical cross-sections of less than 100 nm but can be hundreds of
microns long. This later class includes the well-described carbon nanotubes, which have a
hollow interior, while other types of nanowires made of other materials are frequently solid
[30,31]. Other shapes of nanomaterials are emerging concurrent with technological
advancements, such as tetrapod-like ZnO nanostructures[32] and are discussed later in
section 5.4. Because nanoparticles can be readily and efficiently synthesized from a wide
variety of materials, including semiconductors, which can participate in cellular redox-
reactions and have photocatalytic activity, they are increasingly being considered for use in
biomedical applications and are the focus of this review.
3. Toxicology concerns of ZnO nanoparticles
Although nanoparticles of many different types of materials can be produced, compatibility
issues with living cells limits the types of nanomaterials under consideration for use in
biomedical applications. ZnO is considered to be a “GRAS” (generally recognized as safe)
substance by the FDA. However, the GRAS designation most commonly refers to materials
in the micron to larger size range, as even these substances when reduced to the nanoscale
can develop new actions of toxicity. As a result, a detailed evaluation of nanomaterial
toxicity in both in vitro and in vivo systems is needed, as well as identifying means to reduce
unwanted toxicity. One common approach to increase biocompatibility and reduce particle
aggregation involves coating nanoparticles with discrete sized polymers to render them less
toxic, more likely to be taken up by cells, and potentially more suitable for drug delivery
applications [33].
The primary means by which inadvertent nanoparticle exposure in humans can occur is via
inhalation, ingestion, or dermal contact. After gaining access to the circulatory system,
nanoparticles can be distributed throughout the body and to specific organs [34,35], and
taken up by cells through phagocytic or endocytic mechanisms [18]. The liver, heart, spleen,
pancreas and bone all appear to be targeted sites of ZnO nanoparticles in mice [36], and
inhalation of these particles in rats produces potent yet reversible pulmonary inflammation
[37]. In humans, a common occupational pulmonary illness known as metal fume fever, an
influenza-like illness resulting from inflammation of the respiratory track, occurs when
unprotected metal workers inhale metal fumes such as zinc oxide. Another common
exposure route of ZnO nanoparticles in humans occurs via topical application of sunscreens
and cosmetic products which incorporates these particles due to their UV absorption and
transparent properties. While there remains some concern whether ZnO nanoparticles in
Rasmussen et al. Page 4
Expert Opin Drug Deliv. Author manuscript; available in PMC 2011 September 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
these products can enter the body and cause toxicity, the majority of studies indicate that
ZnO nanoparticles do not penetrate the skin and cause recognizable illness [38,39].
The mechanisms of cytotoxicity from ZnO nanoparticles are not completely understood, but
generation of reactive oxygen species (ROS) is believed to be a major component. When
nanoparticles interact with cells, cellular defense mechanisms are activated to minimize
damage. However, if ROS production exceeds the antioxidative defensive capacity of the
cell, it results in oxidative damage of biomolecules which can lead to cell death [40,41]. Nel
et al. has described ROS oxidative stress as a three-tier model [2]. Tier 1 involves increases
in antioxidant enzymes to start the initial antioxidant defense, followed by Tier 2 which
includes an increase in potent pro-inflammatory cytokines leading to inflammation, while
Tier 3 is characterized by mitochondrial perturbation resulting in cellular death by apoptosis
or necrosis. All three of these levels have been observed for ZnO nanoparticles in
immortalized phagocytic or bronchial epithelial cells leading to damage of lipids, proteins
and DNA, increased release of lactate dehydrogenase, and death by either necrosis or
apoptosis [2,12,37,42,43].
Studies have recorded some degree of toxicity from ZnO nanoparticles in a wide array of
organisms including bacteria, macroalgae, yeast, protozoa, zebrafish, and mice [44–47].
Some of this toxicity has been attributed to the potential dissolvability of ZnO nanoparticles
into free Zn2+ ions [2,48,49], while others reports indicate that particle dissolution into Zn2+
ions is not a major mechanism of cytotoxicity [42,45,50,51]. These differences in
nanoparticle dissolution properties may likely be related to differences in nanoparticle
synthesis conditions and procedures. Typically, physiological levels of zinc are recognized
to be important for a variety of normal growth and developmental processes, as well as
regulation of the immune system by controlling the activity of many different types of
enzymes including transcription factors, metalloproteinases, and polymerases [52,53]. Under
normal conditions, the cell has a relatively high concentration of zinc bound to various
proteins, while the level of free Zn2+ ions remain very low and tightly regulated by
homeostatic mechanisms [52,54]. Excess zinc can be harmful, however, with intracellular
zinc accumulation implicated in neuronal toxicity and brain injury [55]. Excess zinc
consumption or inhalation has also been shown to cause ataxia and metal fume fever,
respectively [37]. For instances where appreciable nanoparticle dissolution can occur, such
as in acidic environments including intracellular lysosomal compartments, hydrated zinc
ions in conjunction with intact ZnO nanoparticles, are suggested to lead to mitochondrial
damage and disruption of cellular zinc homeostasis leading to cell death. The ultimate
cytoprotective or toxic roles of zinc likely reflect the route of administration and dosage,
with high concentrations of zinc salt counter-ions capable of causing cell membrane damage
on their own due to osmotic disruption. Nevertheless, reduction of ZnO to the nanoscale has
been shown to reveal actions of toxicity that appear to preferentially target rapidly dividing
cancerous cells [10,11], which could serve as a foundation for developing novel cancer
therapeutics.
4. Nanoparticles and Cancer Treatment
The use of nanomaterials as pharmaceutical carriers to enhance in vivo anti-tumor efficacy
has been considered for more than 30 years [56]. The first studies on the clinical potential of
nano-drug carriers as liposomes occurred in the mid-1970’s [57] where treatment of tumor
bearing mice with liposome-entrapped actinomycin D was shown to significantly prolong
survival. Today, the use of nanomaterials for delivery of pharmaceutical and diagnostics
agents remains at the forefront of nanomedicine, where recent improvements have been
described by conjugating cell specific ligands to the surface of nanoparticles resulting in
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greater control of drug targeting at the tissue and cellular levels, and by encapsulating drugs
within nanoparticles to significantly improve drug release profiles [58–60].
Numerous preclinical studies using nanoparticle-targeted therapies in oncology are
underway, although some ideas have already been brought to the clinic (Tables 1–3). The
FDA-approved Abraxane®, an albumin-paclitaxel (Taxol®) nanoparticle treatment for
metastatic breast cancer has shown a promising overall response rate of 33%, compared with
19% for Taxol® alone in a randomized, open-labeled trail of 454 patients. Overall side
effects were fewer with the nano-based drug even though it delivered a 50% higher dose of
the active Taxol® than the conventional formulation [8]. An additional example is Myocet®,
a liposomal formulation of doxorubicin that has significantly improved the therapeutic
index, the ratio of the amount of an agent that causes the desired therapeutic effect to that
which causes unwanted cell death, compared with conventional doxorubicin. The
development of Myocet® through nanotechnology has yielded a less cardiotoxic, better
tolerated, and equally efficacious doxorubicin capable of extending the therapeutic options
for the management of breast cancer [61].
In addition to nano-drug carriers, interest is growing regarding the ability of certain
nanomaterials to mediate anti-cancer effects on their own, including metal oxides. One
approach involves the successful use of TiO2 metal oxide nanoparticles to kill cancer cells
when UV irradiated [62–64]. In these studies, HeLa cells were completely killed in the
presence of TiO2 andUV irradiation, and in vivo tumor growth arrested up to 30 days, while
no cancer cell killing was observed in the absence of TiO2 nanoparticles and UV light.
Although effective for the treatment of skin cancer, a limitation of this photodynamic
nanomedicine-based approach is the inability of UV light to penetrate more than 1 mm
through skin, unless fiber optics or surgery are used in conjunction.
Nanomedicine-based hyperthermia is another promising therapy for cancer treatment.
Infusing a tumor with magnetic or metal nanoparticles, and then exposing the patient to an
alternating magnetic field or shortwave radiofrequency energy produces heat which warms
areas immediately adjacent to the nanoparticles [65,66]. When sufficient supernormal
temperatures are reached, the tumor cells are killed without harming surrounding healthy
tissue. Both photodynamic and hyperthermic nanoparticle-based cancer approaches share
the challenge of preferentially accumulating at tumor sites, unless targeting strategies are
also employed. In addition to the above described applications, emerging approaches using
zinc oxide nanoparticles are gaining interest for the development for new anti-cancer
therapeutics and are described below.
5. ZnO Nanoparticle Properties Useful for Biomedical and Cancer
Applications
ZnO is a conventional wide band-gap semiconductor that has been highly explored in
multiple areas of science. ZnO nanomaterials have been used as semiconductors in
microelectronic devices and for accelerating degradation of water pollutants via
photocatalytic activity. Due to its inherent ability to absorb UV irradiation and optical
transparency, ZnO nanoparticles are used in the cosmetic industry, typically in sunscreens
and facial creams [38,67]. Their recognized antibacterial properties are also encouraging a
variety of antimicrobial applications [68,69]. ZnO nanoparticles have gained interest in other
biomedical applications based on their high stability, inherent photoluminescence properties
which can be useful in biosensing applications, and wide band-gap semiconductor properties
useful in photocatalytic systems and promotion of reactive oxygen species generation. ZnO
nanoparticles have recently shown promise as cholesterol biosensors, dietary modulators for
hydrolase activity relevant to controlling diabetes and hyperlipaemia, as well as cell imaging
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[11,70]. Additionally, ZnO nanoparticles show promise in modulating allergic reactions via
inhibition of mast cell degranulation [71]. The diversity of these activities has popularized
ZnO nanomaterials in interdisciplinary research communities involving physicists, chemists,
and biologists.
Although ZnO nanoparticles have been used in the cosmetic industry for many years, they
have only recently been explored for use in cancer applications or as active drugs
themselves. The question arises as to what makes ZnO nanoparticles an attractive
consideration. Clearly, this is not simply a matter of being able to synthesize nanoparticles,
as nanoparticles of many different material systems can be produced. The practical
limitation for biomedical applications largely comes down to issues of biocompatibility. In
this regard, ZnO nanomaterials, at least sizes larger than 100 nm, are considered to be
relatively biocompatible, with bulk ZnO being recognized as a GRAS substance by the FDA
making them reasonable choices for drug delivery. ZnO nanowires have been shown to be
biodegradable and to eventually dissolve into ions that can be adsorbed by the body and
become part of the nutritional cycle, and thereby proposed for in vivo biosensing and
biodetection applications [72]. The ability to synthesize ZnO into hollow nanotube-type
structures [30,31] also makes them reasonable choices for drug delivery, particularly slow
drug release applications.
One of the primary advantages for considering ZnO nanoparticles for use in cancer is the
inherent preferential cytotoxicity against cancer cells in vitro [10,11]. It is anticipated that
their cancer cell selectivity may be even further improved by engineering design to
minimize harmful effects to normal body cells, which has been observed to occur at very
high concentrations of ZnO nanoparticles, particularly those in the smaller size range of 4–
20 nm [73]. In this regard, the surface chemistry of ZnO nanoparticles readily lends them to
functionalization with targeting proteins or chemical groups, and may be a key to rendering
them benign to normal cells while still retaining their cancer targeting and killing properties.
The electrostatic characteristics of ZnO nanoparticles are another useful feature for
biomedical applications. Zinc oxide nanoparticles typically have neutral hydroxyl groups
attached to their surface, which plays a key role in their surface charge behavior [74,75]. In
aqueous medium and at high pH, the chemisorbed protons (H+) move out from the particle
surface leaving a negatively charged surface with partially bonded oxygen atoms (ZnO−). At
lower pH, protons from the environment are likely transferred to the particle surface, leading
to a positive charge from surface ZnOH2+ groups. The isoelectric point of 9–10 [76]
indicates that ZnO nanoparticles will have a strong positive surface charge under
physiological conditions. Given that cancer cells frequently contain a high concentration of
anionic phospholipids on their outer membrane and large membrane potentials [23–25],
interactions with positively charged ZnO nanoparticles are expected to be driven by
electrostatic interactions, thereby promoting cellular uptake, phagocytosis and ultimate
cytotoxicity.
The concentration of various chemical groups (-ZnOH2+, -ZnOH, -ZnO−) on the surface of
ZnO nanoparticles is pH dependent [77]. The availability of chemical reactive groups lends
ZnO nanoparticles to antibody/protein functionalization via N-hydroxysuccinimide/1-
ethyl-3-(3-dimethyl-aminopropyl) carbodiimide (NHS/EDC) coupling chemistry [78], as
well as other standard coupling approaches, which can further improve cancer cell targeting.
ZnO nanoparticles have also been shown to exhibit strong protein adsorption properties,
which can be used to modulate cytotoxicity, metabolism or other cellular responses [79].
Another important feature of ZnO nanoparticles is the relatively straightforward process that
allows their size and size distribution to be controlled. Studies demonstrate that the cytotoxic
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properties of ZnO nanoparticles against cancerous cells is directly related to size, with
smaller nanoparticles exhibiting greater toxicity [13,15,73]. By tailoring nanoparticle size, it
is possible to take the greatest advantage of the EPR/enhanced permeation and retention
effect for increasing intra-tumor concentrations. Another important consideration is that
hydrophilic nanoparticles of 100 nm size or less tend to remain in circulation considerably
longer and are more likely to avoid clearance by macrophages and rapid serum clearance by
the reticuloendothelial system [17]. In contrast, particles with a preponderance of
hydrophobic surfaces tend to be preferentially taken up by the liver, followed by the spleen
and lungs [17]. The ability to modify the surface and electrostatic characteristics (zeta-
potential) of ZnO nanoparticles is a desirable feature, as well as their spherical morphology
which is well suited for removal from the blood stream by the kidneys to help avoid build up
of these materials in the liver. The zeta potential of metal oxide nanoparticles can be varied
from −30 mV in uncoated samples to +50 mV when coated with cationic surfactants such as
CTAB (cetyltrimethyl ammonium bromide), by using different anionic, cationic and non-
ionic surface groups including polymethyl methacrylate, sodium dodecyl sulfate, bovine
serum albumin, and by varying reaction medium and chemical precursors [80,81]. The
detailed evaluation of variations in ZnO nanoparticle electrostatic charge in in vivo systems
is important for identifying the optimal charge needed to mediate cancer cell adhesion and
cytotoxicity, yet avoid rapid circulation clearance and end-organ toxicities.
Another feature of ZnO nanoparticles, as stated earlier, is their ability to induce reactive
oxygen species (ROS) generation, which can lead to cell death when the antioxidative
capacity of the cell is exceeded [12,41,82–84]. The ability of ZnO nanoparticles to generate
ROS is related to their semiconductor properties. Unlike metals, which have a continuum of
electronic states, the electrons in semiconductors can have energies only within certain
bands. The void region which extends from the top of the filled valence band to the bottom
of the vacant conduction band is called the band gap and is ~3.3 eV for crystalline ZnO [85].
Consequently, light of certain wavelengths (i.e. UV) contains sufficient energy to promote
electrons (e−) to the conduction band to leave behind electron holes (h+), or unoccupied
states in the valence band. Electrons and holes often recombine quickly, but can also migrate
to the nanoparticle surface where they react with adsorbed species enabling 1) electrons to
react with oxygen, and 2) holes to react with hydroxyl ions or water to form superoxide and
hydroxyl radicals. Such photo-oxidations by ZnO have been traditionally used for
photocatalytic oxidation of organic and inorganic pollutants, and sensitizers for the
photodestruction of cancer cells [14,62,63] and bacteria [15] via oxidative damage.
However, for nanoscale ZnO, large numbers of valence band holes and/or conduction band
electrons are thought to be available to serve in redox reactions even in the absence of UV
light [51]. One of the reasons is that as ZnO nanoparticle size decreases, so does the
nanocrystal quality, which results in increased interstitial zinc ions and oxygen vacancies,
and possibly donor/acceptor impurities [86]. These crystal defects can lead to a large
number of electron-hole pairs (e− − h+). The holes are powerful oxidants and can split water
molecules derived from the ZnO aqueous environment into H+ and OH−. The conduction
band electrons are good reducers and can move to the particle surface to react with dissolved
oxygen molecules to generate superoxide radical anions (O2•−), which in turn react with H+
to generate (HO2•) radicals. These HO2• molecules can then produce hydrogen peroxide
anions (HO2−) following a subsequent encounter with electrons. Hydrogen peroxide anions
can then react with hydrogen ions to produce hydrogen peroxide (H2O2) [87,88]. The
relative positions of the band edges for the conduction and valence band for ZnO, and the
redox potential for adsorbed substances provides a sufficiently large overpotential (voltage
differences) to drive redox reactions and ROS generation in cellular environments [89–91].
The various ROS molecules produced in this fashion can trigger redox-cycling cascades in
the cell, or on adjacent cell membranes, leading to depletion of endogenous cellular reserves
of antioxidants such that irreparable oxidative damage to cells occurs.
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The doping of ZnO nanoparticles with transition metal ions has been demonstrated
[85,92,93], and may be another approach to improve their therapeutic potential as transition
metals can potentiate redox-cycling cascades. It is postulated that incorporation of Fe+3 into
the ZnO crystal lattice enhances the particle’s ability to generate ROS by catalyzing the
dissociation of H2O2 to a hydroxyl radical and hydroxide ion, or to a hydrogen ion and
hydroperoxy radical following the Fenton’s reaction [94,95]. In support of this, recent
studies have shown that Fe+3 supported on bulk ZnO improves catalytic activity for H2O2
production [87], and introduction of free transition metal ions can induce protein oxidation
and redox state within cells [96]. Although a conflicting report suggests iron-doping of ZnO
may not function in this manner [97], recent data from our laboratory is consistent with
increased ROS capacity and may reflect differences in nanoparticle synthesis resulting in
variations in surface structure and charge. Thus, the engineering of metal oxide
nanoparticles to incorporate metal dopants may be a means to enhance ROS generation
leading to improved cancer cell killing.
5.1. ZnO Nanoparticles and Cancer Cell Cytotoxicity
Several studies have suggested an increase in in vitro cytotoxicity with nanophase ZnO
compared to micron-sized ZnO for several types of cancers including glioma, breast, bone,
colon, and leukemias and lymphomas [10,11,13,98]. In most of these studies, however, a
systematic review of cancer cell cytotoxicity compared to relevant non-immortalized cell
types was not performed. Perhaps the most compelling evidence of ZnO preferential toxicity
comes from controlled studies comparing nanoparticle susceptibility of cancerous cells to
primary non-immortalized cells of identical lineage. These studies showed that cancerous
cells of lymphocytic lineage were ~28–35 times more susceptible to ZnO nanoparticle-
induced cytotoxicity compared to their normal counterparts [10,11,73]. This high degree of
selective cancer cell killing exceeds the ex vivo therapeutic indices of ≤ 10 reported for
commonly used chemotherapeutic drugs such as doxorubicin and carboplatin against a
variety of leukemias, lymphomas, and solid tumors using similar biological assays. The
preferential cytotoxicity was found to be dependent upon on the proliferation status of cells,
with rapidly dividing cells being the most susceptible [10,73]. Based on a growing body of
evidence, ROS production is proposed as a key cytotoxic mechanism of ZnO nanoparticles
[43,43,50,73] leading to cell death via an apoptotic mechanism.
Based on the self-lighting photodynamic therapy concept, photoactivation of ZnO
nanoparticles is predicted to lead to greater levels of ROS release which, if effectively
targeted to cancer cells, will lead to their selective destruction. Recent supporting studies
have described the ability of ZnO nanoparticles conjugated to porphyrin to synergistically
induce cytotoxicity in ovarian cancer upon exposure to UV A light, while little cytotoxicity
was observed under dark conditions, or with UV exposure in the absence of nanoparticles
[16]. Similar studies have demonstrated that co-administration of ZnO nanoparticles and the
chemotherapeutic drug, daunorubicin, resulted in synergistic cytotoxic effects on leukemic
cancer cells, which was further enhanced by UV irradiation [13]. Collectively, these reports
indicate that photoactivation of ZnO nanoparticles conjugated to tumor ligands may be
useful for the targeted destruction of cancer cells. Future efforts in this area of research are
expected to investigate direct drug conjugation or encapsulation within the ZnO nanocrystal
structure to further improve anti-cancer efficacy as discussed below.
5.2. Metal Oxide Nanoparticles as Vehicles for Drug Delivery
The development of tumor-specific nanoparticles as vehicles for self-sustained drug delivery
is currently an area of intense research with the potential to revolutionize cancer treatment.
Nanotechnology may make it possible to improve the delivery of poorly water-soluble
drugs, target delivery of drugs to specific cell or tissue sites, co-deliver two or more drugs,
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and aid in the visualization of drug site delivery by combining therapeutic agents with
imaging modalities [99]. Using nanoparticles for drug delivery of anticancer agents has
significant advantages including the ability to target specific locations in the body, reduce
the overall amount of drug used, and the potential to reduce drug concentrations at nontarget
sites resulting in fewer side effects. Recently, the use of ZnO quantum dots loaded with
doxorubicin has proved to be an effective drug carrier characterized by an initial rapid drug
release followed by a controlled release in vitro [100]. In this study, ZnO nanoparticles were
encapsulated with chitosan to enhance the nanomaterial stability due to its hydrophilicity
and cationic charge characteristics. Although ZnO nanomaterials have only recently been
investigated for use as a drug delivery system, the feasibility of this approach has been
demonstrated in related metal oxide systems. Iron oxide magnetic nanoparticles have been
successfully used for loading high doses of water-insoluble anticancer agents to mediate
dose-dependent anti-proliferative effects in breast and prostate cancer lines [101]. Iron oxide
nanoparticles have also been used to deliver therapeutic agents by conjugation to both a
chemotherapeutic agent, methotrexate, and a cancer targeting ligand, chlorotoxin [102].
These multifunctional nanoparticles showed increased cytotoxicity to tumor cells and
prolonged tumor retention in vivo. Cerium oxide nanoparticles loaded with
carboxybenzenesulfonamide have also been used to inhibit human carbonic anhydrase, a
metalloenzyme associated with glaucoma, a major cause of blindness [103]. Thus, the
relative biocompatibility of metal oxide nanomaterials and the ability to functionalize them
with targeting moieties make them important for consideration as drug release platforms.
5.3. Metal Oxide Nanoparticles and Tumor Imaging and Early Cancer Detection
Interest is growing regarding the use of ZnO and other metal oxide nanomaterials for use as
biomarkers for cancer diagnosis, screening, and imaging. Recent studies have shown that
ZnO nanoparticle cores capped with polymethyl methacrylate are useful in the detection of
low abundant biomarkers [104]. These nanobeads work by facilitating surface absorption of
peptide/proteins from cell extracts enabling increased sensitivity and accuracy of cancer
biomarker detection using mass spectrometry. Using another approach, a ZnO nanorod-
based cancer biomarker assay has been developed for high-throughput detection of ultralow
levels of the telomerase activity for cancer diagnosis and screening [105].
In an additional approach, multiple reports have described the successful use of iron oxide
nanoparticles as contrast agents for cancer detection. Superparamagnetic oxide nanoparticles
coated with a cell resistant polymer have been shown to accumulate within tumor sites via
the EPR/enhanced permeation and retention effect in tumor xenograft mice model using
magnetic resonance imaging [106]. In another report, the surface of nanoparticles composed
of an iron oxide core and oleic acid coating were modified with various pluronic and tetronic
block copolymers and shown to provide superior in-vivo tumor imaging properties compared
to Feridex IV, a commonly used contrast agent [107]. These modified nanoparticles
exhibited an extended systemic circulation half-life and reduced clearance properties
allowing them to diffuse throughout the tumor vasculature to act as whole tumor contrast
agents. While the superparamagnetic properties of iron oxide nanoparticles offer an
advantage for magnetic resonance imaging compared to ZnO, ZnO composite nanomaterials
may ultimately prove useful for tumor imaging in the future.
5.4. Metal Oxide Nanoparticles and Targeted Gene Delivery
Nanoparticles are also being studied for use as vehicles for targeted gene delivery to tumor
sites. One of the advantages of this approach is that the enclosure of the expression plasmid,
or conjugation/absorption of the nucleic acid to the nanoparticle surface ensures safe and
efficient gene delivery to the desired tissue. Another advantage relies on the capability of
nanoparticles to be taken up by specific cells and internalized to the nucleus according to
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their surface chemistry. The feasibility of this approach has been validated by a growing
number of studies including the reported in vivo studies demonstrating inhibition of
metastasis in melanoma tumor bearing mice treated with poly-L-lysine modified iron oxide
nanoparticles carrying the NM23-H1 gene [108]. These findings are consistent with reports
that this gene product inhibits metastasis in certain types of cancers. A relatively new non-
invasive nanoparticle vehicle called a tetrapod avoids the requirement of cellular
internationalization. These nanomaterials can be made of various materials and possess four
needle-shaped legs reminiscent of the mechanism by which phages deliver genetic material
to bacteria. Recently, ZnO tetrapod-like nanostructures have been synthesized as novel
carriers for gene delivery. These functionalized tetrapods, consisting of silica-coated amino-
modified tetrapod-like ZnO nanostructures, are able to effectively bind plasmid DNA
through electrostatic interactions and enhance transfection efficiency of A375 cells [32,109].
Polycation-capped ZnO quantum dots have been recently developed and shown to mediate
efficient DNA transfer into COS-7 cells, and at the same time allow for real-time imaging of
gene transfer [110]. Thus, with continued research, ZnO and metal oxide nanomaterials may
provide an effective means for targeted gene delivery and gene silencing for next-generation
cancer applications.
6. ZnO Nanoparticles and Proinflammatory Cytokines
ZnO nanoparticle exposure has been shown to induce the production of a variety of pro-
inflammatory cytokines, including TNF-α, IFN-γ and IL-12, in in vitro and in vivo
pulmonary inhalation studies [37,73,111,112]. The ability of ZnO nanoparticles to induce
pro-inflammatory cytokines at nanoparticle concentrations below those causing appreciable
cell death suggests that, when used at appropriate concentrations, they could enhance tumor
cell killing through the production of TNF-α (tumor necrosis factor), a cytokine named for
its potent anti-tumor activities [113]. Nanoparticle-induced cytokines could also facilitate
effective anti-cancer actions by eliciting a cytokine profile crucial for directing the
development of Th1-mediated immunity [114]. The Th1 lymphocyte subset plays an
essential role in enhancing the natural cytotoxic potential of natural killer cells and T
cytotoxic cells against cancer cells. As high level or chronic exposure to TNF-α has been
shown to produce serious detrimental effects on the host [113], the magnitude of TNF-α and
other pro-inflammatory cytokines, and their delivery to tumor sites will undoubtedly be
important parameters when considering ZnO nanoparticles for biomedical purposes to
achieve desired therapeutic response without eliciting potential systemic damaging effects.
Thus, a careful titration of ZnO nanoparticle-based therapeutic interventions may be
successful in elevating a group of cytokines important for eliciting a Th1-mediated immune
response with effective anti-cancer actions without exacerbating the recognized relationship
between chronic inflammation and tumorigenesis.
7. Conclusion
As nanotechnology increases in scale and novelty, new applications and uses are continually
being discovered. Some of the most exciting advances include using nanotechnology to
combat cancer. Currently, some nanobased cancer treatments are in clinical use or the
development pipeline. This review has focused on ZnO nanoparticles, which have only
recently begun to be investigated with respect to cancer applications. Specific properties and
characteristics of ZnO nanoparticles, such as their inherent toxicity against cancerous cells,
at least for cells of lymphocytic origin, their ability to induce intracellular ROS generation
leading to death via an apoptotic mechanism, and their physiochemical properties leading to
cellular uptake and ease of functionalization make them an appealing candidate for
biomedical applications.
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8. Expert Opinion
Nanotechnology has already provided significant breakthroughs in medicine and cancer
applications. The potential benefits of metal oxide nanomaterials for tumor imaging,
controlled drug delivery, and targeted cancer cell killing can be enormous and may offer
clinical therapeutic platforms that simply do not exist today. There are multiple
characteristics of ZnO that make these nanomaterials attractive considerations including
their versatility, relative ease of synthesis, ability to tailor their physiochemical
characteristics, ability to functionalize them with chemotherapeutic drugs and cancer
targeting molecules, and their desirable cancer cell cytotoxicity profile. By building upon
the inherent cancer cell cytotoxicity of ZnO nanoparticles, and fine tuning their size, shape
and surface properties during the synthesis process, it may be possible to identify the
physiochemical properties that take the greatest advantage of the EPR/enhanced permeation
and retention effect and bypass multidrug resistance of the cell membrane. Likewise, the
optimum balance of cationic surface charge to encourage cell membrane interactions
without promoting rapid clearance from serum by macrophages and the RES may be
identified, as well as optimum morphology to increase the likelihood of recognizing specific
biological targets and control blood vessel wall adhesion strength relevant to cellular
internalization. It is the expectation that systematic investigations can identify ZnO
nanomaterial characteristics capable of overcoming at least some of the major barriers
needed for more effective cancer treatments.
Although metal oxide nanomaterials hold potential for improving human health, there are
still multiple challenges to bring these materials to the clinic. One of the obstacles is that
there is current misunderstanding regarding the biological effects and cytotoxicity profiles of
ZnO nanoparticles. The discrepancies in the literature are likely attributable to the lack of
common understanding between life scientists and materials scientists regarding the other’s
limitations and capabilities. Nanoparticles are not necessarily identical from batch-to-batch
and may display alterations in surface chemistry or size distribution. Life scientists might
not appreciate the difficulty in controlling the synthesis process, while nanotechnologists
might not appreciate the sensitivity of mammalian cells to these variations. There is also
concern that researchers may treat ZnO nanoparticles made by different synthesis methods
as a single entity with insufficient regard to their potential to exert different biological
responses. Other confounding factors include differences in handling, pH variations of the
dispersion media, long term stability versus freshly prepared nanoparticles, impurities,
humidity variations during the synthesis, and variations in aspect ratio or agglomeration
potential. In sum, a lack of careful surface and physiochemical characterizations of ZnO
nanoparticles has led to much of the current confusion regarding the biological responses
elicited from these materials. What is needed to avoid these types of problems is a better
understanding of the intersecting areas of science between nanomaterial scientists and
biologists, such that collaborations allow for the effective exchange of information and
methodology to advance the field.
Currently, the work with metal oxide nanoparticles in medicine is at a preliminary stage.
Nevertheless, the use of metal oxide nanomaterials represents an expanding domain for the
diagnosis and treatment of cancer. Currently insufficient in vivo data is available to know the
biological effects of these materials with respect to inflammation and functional alterations
at the cellular or whole body level. There is a need to deepen this knowledge to determine if
potential advantages for these nanomedicines outweigh potential dangers associated with
nanotoxicity. Although ZnO nanoparticles are widely used in the cosmetic industry and
evidence against skin penetration is encouraging, there remains some debate regarding
epidermal penetration and lingering questions regarding the safety of these materials. Most
studies have been performed in vitro with limited longitudinal in vivo studies to assess long-
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term effects to kidneys, liver, and spleen, and whether the particles are cleared from the
body, dissolve, or remain indefinitely. As drug carriers, ZnO nanomaterials have an
advantage over dissolvable polymers in that they can exist in the body for considerable
periods of time. Nanoparticles can enhance the circulation half-life of drugs to several hours
allowing time to reach the cancer, while single drug molecule half-lives are usually limited
to a few minutes and can require repeated injections. Nanoparticle drug carriers also have
the advantage of being small enough to pass through the capillaries yet large enough not to
slip through endothelial gap junctions. However, ZnO nanoparticles have a potential
disadvantage to build up in the body and cause organ toxicities or breakdown in
unpredictable ways. The ability of ZnO nanoparticles to induce expression of
proinflammatory cytokines under certain conditions also indicates that care to dosing
regimens will be essential given the recognized relationship of chronic inflammation and
tumorigenesis. Although it is tempting to speculate that ZnO nanomaterials may ultimately
be developed into a next generation cancer treatment, clearly more data is needed to
unequivocally determine their long-term health risks.
For the in vivo potential of nanotechnology in cancer therapy to be fully realized,
nanomaterials have to get “smarter”, meaning better able to destroy pathogenic cells while
producing negligible off-target effects to normal cells and tissues. For this to occur, it is
essential to gain a clear understanding of both physiochemical determinants and
physiological processes, which will likely vary with respect to the type and location of the
particular cancer, as well as the method of delivery into the body. The future of
nanomedicine will depend upon the intelligent design of nanomaterials based around a
thorough understanding of cancer biology rather than trying to force the application of
popular nanomaterials, including ZnO, to cancer treatment. It is important that synergies
between clinicians, biologists and material scientists be strengthened so that future research
focuses on developing the tools needed by clinicians rather than what basic scientists
perceive as important. An additional stumbling block is the uncertainty of whether
nanotechnology-specific medical regulations will be implemented that could add further
requirements to the approval process and thereby hamper the commercialization potential.
Nanomedicine is still technology driven with many scientific challenges lying ahead.
However, it represents a growing field with promise to address the long standing need for
new and improved anti-cancer therapies.
Article Highlights
• There is an urgent need to develop new anti-cancer agents that are better able to
target cancer cells while sparing normal cells and tissues. Nanomedicine,
including the use of ZnO nanoparticles, offers considerable promise in this
regard.
• The development of new physical and chemical properties that can accompany
reduction of materials to the nanoscale offers advantages for developing anti-
cancer agents, including the ability to tailor the electrostatic properties and size
of nanoparticles to promote cellular uptake and make use of the enhance
permeation and retention effect (EPR) to promote intra-tumor accumulation.
• Reduction of ZnO to the nanoscale has toxicological ramifications, including the
generation of reactive oxidative species, which may be exploited in combination
with cancer-specific targeting strategies for developing novel therapeutics.
• There is an increasing amount of attention on nanomaterials and their successful
use in cancer treatment regimens. The potential of ZnO and other metal oxide
nanoparticles is beginning to be realized.
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• ZnO nanoparticles have multiple properties that are useful for biomedical
applications including favorable band gap, electrostatic charge, surface
chemistry, and potentiation of redox-cycling cascades. Notably, ZnO
nanoparticles appear to have inherent anti-cancer cytotoxicity actions.
• A variety of metal oxide nanoparticles have shown success for use as vehicles
for drug delivery, targeted gene delivery, and tumor imaging. The use of metal
oxide ZnO nanoparticles in these applications is beginning to be explored with
some success in areas of drug carrier and targeted gene delivery.
• Careful titration of ZnO nanoparticle-based therapeutic interventions may be
successful in increasing anti-tumor cytokine production and exerting cancer cell
destruction, without eliciting harmful systemic proinflammatory effects.
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Table 1
Cancer Nanoparticle-based therapeutics on the market *
Product Type of Nanomaterial Indication Company Phase
Abraxane [115] Paclitaxel-albumin Nanoparticle Lung cancer Breast cancer Abraxis BioScience, AstraZeneca On market
Myocet [3] Liposomal doxorubicin Breast cancer Zeneus Pharma On market
Depocyt [3] Liposomal cytarabine Cancer SkyePharma On market
Doxil/Caelyx[3] Liposomal doxorubicin Cancer Ortho Biotech, Schering-Plough On market
DaunoXome [115] Liposomal daunorubicin Cancer Gilead Sciences On market
Genexol-PM [115] Methoxy-PEG-poly(D, L-lactide) taxol Metastatic breast cancer Samyang On market
Neulasta [115] PEG–GCSF Neutropenia associated with
cancer chemotherapy
Amgen On market
Oncaspar [3] PEG–L-asparaginase Acute lymphoblastic leukemia Enzon On market
Resovist [3] Iron nanoparticles Liver tumor imaging Schering On market
Feridex/Endorem [3] Iron nanoparticles Liver tumor imaging Advanced Magnetics, Guerbet On market
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Table 2
Cancer Nanoparticle-based therapeutics in the clinical development pipeline*
Product Type of Nanomaterial Indication Company Phase
Xyotax [115] Polyglutamate paclitaxel Non-small-cell lung cancer,
ovarian cancer
Cell Therapeutics Phase III
Onco TCS [115] Liposomal vincristine Non-Hodgkin’s lymphoma Inex, Enzon Phase II/III
NX 211 [116] Liposomal lurtotecan Solid tumors Gilead Phase II
Panzem NCD [117] 2-methoxyestradiol NanoCrystal Glioblastoma EntreMed Phase II
OSI-211 [115] Liposomal lurtotecan Ovarian cancer OSI Pharmaceuticals Phase II
SLIT Cisplatin [115] Liposomal cisplatin Progressive osteogenic
sarcoma metastatic to the lung
Transave Phase II
ProLindac [115] HPMA copolymer–DACH platinate Ovarian cancers Access Pharmaceuticals Phase II
SP1049C [115] Pluronic block- copolymer doxorubicin Esophageal carcinoma Supratek Pharma Phase II
Aroplatin [118] Liposomal platinum Solid tumors Antigenics Phase I/II
Transdrug [115] Poly(iso-hexyl cyanoacrylate) doxorubicin Hepatocellular carcinoma BioAlliance Pharma Phase I/II
Hepacid [115] PEG–arginine deaminase Hepatocellular carcinoma Phoenix Phase I/II
CT-2106 [115] Polyglutamate camptothecin Colorectal and ovarian
cancers
Cell Therapeutics Phase I/II
Prothecan [115] PEG–camptothecin Various cancers Enzon Phase I/II
Sarcodoxome [115] Liposomal doxorubicin Soft tissue sarcoma GP-Pharm Phase I/II
L-Annamycin [115] Liposomal annamycin Acute lymphocytic leukemia,
acute myeloid
Callisto Phase I
Al-850 [3] Paclitaxel nanoparticles Solid tumors Acusphere Phase I
Aurimune [119] TNF α-bound colloidal gold Solid tumors Cytimmune Phase I
IT-101 [115] Polycyclodextrin camptothecin Metastatic solid tumors Insert Therapeutics Phase I
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Table 3
Cancer Nanoparticle-based therapeutics in the preclinical development pipeline*
Product/Composition Therapeutic Indication
Auritol [119] Taxol and TNF α-bound colloidal gold Solid tumors
Platform technology[120] PRINT™ nanoparticles Cancer
AuroLase [121] Gold nanoshell Head and neck cancer
Antibody–enzyme-conjugated nanoparticles [122] Antibody-directed enzyme prodrug therapy Ovarian cancer
Pluronic block copolymers [123] Doxorubicin Various cancers
Polymer–lipid hybrid nanoparticles [124] Doxorubicin Solid tumors
Poly(lactic-co-glycolic acid)-block-poly(ethylene glycol) [125] Docetaxel Prostate cancers
Poly(vinyl alcohol) polymeric micelles [126] PVA polymer antitumor activity Neuroblastoma, melanoma
Folic acid-PAMAM dendrimers [127] Methotrexate Epithelial cancer
Poly(glycerol-succinic acid) dendrimers [128] Camptothecin Various cancers
Albumin-bound nanoparticles [129] Doxorubicin, methotrexate Various cancers
Aerosol OT (AOT)-alginate nanoparticles [130] Doxorubicin Breast cancer
Glycol chitosan nanoparticles [131] Doxorubicin Solid tumors
Gold-conjugated cytomegalovirus nanoparticles [132] Phototherapy, gene therapy Solid tumors
Aminosilane-coated iron oxide nanoparticles [65] Thermotherapy Brain tumors
Anti-HER2 antibody-targeted gold/silicon nanoparticles [133] Nanoshell-assisted infrared photothermal
therapy
Metastatic breast cancer
Silica-based nanoparticles [134] Photodynamic therapy Various cancers
PEG, polyethylene glycol; GCSF, granulocyte colony-stimulating factor; HPMA, hydroxypropylmethacrylamide; DACH, diaminocyclohexane;
TNF-α, tumor necrosis factor-α; HER2, human epidermal growth factor receptor 2; PAMAM, polyamidoamine; PVA, polyvinyl alcohol.
*
These nanoparticle-based therapeutics were selected with preference given to late-stage, preclinical, clinical, and approved products covering the
wide range of modalities (e.g., liposomal platforms, dendrimers, etc) employed in the development of nanomedicines to date, and covering the
broad spectrum of cancer types. This is not an exhaustive list.
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